LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 130

Search options

  1. Article ; Online: Of chloroquine and COVID-19.

    Touret, Franck / de Lamballerie, Xavier

    Antiviral research

    2020  Volume 177, Page(s) 104762

    Abstract: Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this ... ...

    Abstract Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
    MeSH term(s) Antiviral Agents/adverse effects ; Antiviral Agents/pharmacology ; Antiviral Agents/standards ; Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; COVID-19 ; China ; Chloroquine/adverse effects ; Chloroquine/pharmacology ; Chloroquine/standards ; Chloroquine/therapeutic use ; Clinical Trials as Topic/standards ; Coronavirus Infections/drug therapy ; Humans ; Hydroxychloroquine/adverse effects ; Hydroxychloroquine/pharmacology ; Hydroxychloroquine/standards ; Hydroxychloroquine/therapeutic use ; Pandemics ; Pneumonia, Viral/drug therapy ; SARS-CoV-2
    Chemical Substances Antiviral Agents ; Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF)
    Keywords covid19
    Language English
    Publishing date 2020-03-05
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2020.104762
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1627: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.

    Driouich, Jean-Sélim / Bernadin, Ornéllie / Touret, Franck / de Lamballerie, Xavier / Nougairède, Antoine

    Antiviral research

    2023  Volume 215, Page(s) 105638

    Abstract: The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In ...

    Abstract The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model to determine whether Sotrovimab retains antiviral activity against these Omicron variants in vivo. Our results show that at exposures consistent with those observed in humans, Sotrovimab remains active against BQ.1.1 and XBB.1, although for BQ.1.1 the efficacy is lower than that observed against the first globally dominant Omicron sublineages BA.1 and BA.2.
    MeSH term(s) Animals ; Cricetinae ; Humans ; COVID-19 ; SARS-CoV-2 ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral
    Chemical Substances sotrovimab (1MTK0BPN8V) ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2023-05-18
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2023.105638
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1627: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Of chloroquine and COVID-19

    Touret, Franck / de Lamballerie, Xavier

    Antiviral Research

    2020  Volume 177, Page(s) 104762

    Keywords Pharmacology ; Virology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2020.104762
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1627: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate.

    Touret, Franck / Baronti, Cécile / Bouzidi, Hawa Sophia / de Lamballerie, Xavier

    Scientific reports

    2022  Volume 12, Issue 1, Page(s) 4683

    Abstract: The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of the ... ...

    Abstract The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of the Omicron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral B.1 BavPat1 D614G strain. We observed that six of these antibodies have lost their ability to neutralize the Omicron variant. Of the antibodies still having neutralizing activity, Sotrovimab/Vir-7831 shows the smallest reduction in activity, with a factor change of 3.1. Cilgavimab/AZD1061 alone shows a reduction in efficacy of 15.8, resulting in a significant loss of activity for the Evusheld cocktail (42.6-fold reduction) in which the other antibody, Tixagevimab, does not retain significant activity against Omicron. Our results suggest that the clinical efficacy of the initially proposed doses should be rapidly evaluated and the possible need to modify doses or propose combination therapies should be considered.
    MeSH term(s) Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral/therapeutic use ; COVID-19/drug therapy ; Humans ; Membrane Glycoproteins ; Neutralization Tests ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral ; Membrane Glycoproteins ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins ; spike protein, SARS-CoV-2 ; tixagevimab ; cilgavimab (1KUR4BN70F) ; sotrovimab (1MTK0BPN8V)
    Language English
    Publishing date 2022-03-18
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-022-08559-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate

    Franck Touret / Cécile Baronti / Hawa Sophia Bouzidi / Xavier de Lamballerie

    Scientific Reports, Vol 12, Iss 1, Pp 1-

    2022  Volume 5

    Abstract: Abstract The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of ... ...

    Abstract Abstract The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of the Omicron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral B.1 BavPat1 D614G strain. We observed that six of these antibodies have lost their ability to neutralize the Omicron variant. Of the antibodies still having neutralizing activity, Sotrovimab/Vir-7831 shows the smallest reduction in activity, with a factor change of 3.1. Cilgavimab/AZD1061 alone shows a reduction in efficacy of 15.8, resulting in a significant loss of activity for the Evusheld cocktail (42.6-fold reduction) in which the other antibody, Tixagevimab, does not retain significant activity against Omicron. Our results suggest that the clinical efficacy of the initially proposed doses should be rapidly evaluated and the possible need to modify doses or propose combination therapies should be considered.
    Keywords Medicine ; R ; Science ; Q
    Language English
    Publishing date 2022-03-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: Of chloroquine and COVID-19

    Touret, Franck / de Lamballerie, Xavier

    Antiviral Res

    Abstract: Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this ... ...

    Abstract Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #4426
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Of chloroquine and COVID-19

    Touret, Franck / De Lamballerie, Xavier

    ISSN: 0166-3542 ; Antiviral Research ; https://www.hal.inserm.fr/inserm-02519612 ; Antiviral Research, Elsevier Masson, 2020, 177, pp.104762. ⟨10.1016/j.antiviral.2020.104762⟩

    2020  

    Abstract: International audience ... Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community ... ...

    Abstract International audience

    Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
    Keywords 2019-nCoV ; Antiviral ; COVID-19 ; Chloroquine ; SARS-CoV-2 ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ; [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; covid19
    Language English
    Publishing date 2020-03-05
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Of chloroquine and COVID-19

    Touret, Franck / De Lamballerie, Xavier

    ISSN: 0166-3542 ; Antiviral Research ; https://www.hal.inserm.fr/inserm-02519612 ; Antiviral Research, Elsevier Masson, 2020, 177, pp.104762. ⟨10.1016/j.antiviral.2020.104762⟩

    2020  

    Abstract: International audience ... Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community ... ...

    Abstract International audience

    Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
    Keywords 2019-nCoV ; Antiviral ; COVID-19 ; Chloroquine ; SARS-CoV-2 ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ; [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; covid19
    Language English
    Publishing date 2020-03-05
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Of chloroquine and COVID-19

    Touret, Franck / De Lamballerie, Xavier

    ISSN: 0166-3542 ; Antiviral Research ; https://www.hal.inserm.fr/inserm-02519612 ; Antiviral Research, Elsevier Masson, 2020, 177, pp.104762. ⟨10.1016/j.antiviral.2020.104762⟩

    2020  

    Abstract: International audience ... Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community ... ...

    Abstract International audience

    Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
    Keywords 2019-nCoV ; Antiviral ; COVID-19 ; Chloroquine ; SARS-CoV-2 ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ; [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; covid19
    Language English
    Publishing date 2020-03-05
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: In vivo activity of Sotrovimab against BQ.1.1 Omicron sublineage

    Driouich, Jean-Selim / Bernadin, Ornellie / Touret, Franck / de Lamballerie, Xavier / Nougairede, Antoine

    bioRxiv

    Abstract: The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1, a sub- ... ...

    Abstract The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1, a sub-variant of BA.5 that is spreading in the USA and Europe. In the present study, we used the hamster model to determine whether Sotrovimab retains antiviral activity against BQ.1.1 in vivo. Our results show that at exposures consistent with those observed in humans, Sotrovimab remains active against BQ.1.1 variant, although at a lower level than that observed against the first globally dominant BA.1 and BA.2 Omicron sublineages.
    Keywords covid19
    Language English
    Publishing date 2023-01-04
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2023.01.04.522629
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top